Yunnan Hansu Biotechnology Co., Ltd (hereinafter referred to as “Hansu “), as the largest single shareholder of Yunnan Hempmon Pharmaceutical Co., Ltd. (hereinafter referred to as ” Hempmon”), held a groundbreaking ceremony on Feb 12th, 2019.
Hempmon as the phaseⅡof the Hansu industrialization project has settled in Airport Industrial Park New Central Yunnan. Hempmon successfully starts up the project with the supports of Yunnan government. The project covers an area of 54 acres, construction scale 58000 square meters, processing industrial hemp capacity of 2000 tons (expanded to 3000 tons), which will become one of the world’s largest industrial hemp extraction & processing enterprises.
Hempmon will independently R&D and construct a full set of production system at leading international standard level. The system includes intelligent storage system, continuous automated processing operating system, industrial preparative chromatography system etc. The completion of the production factory will implement intelligently separation, purification and mass production 13 kinds of spiritual activity cannabinoid material (CBD). At the same time, Hempmon has built a new factory, strictly in accordance with GMP standards, which boasts the best facilities in China. Hempmon owns the production conditions of injection-grade raw materials and high-end preparation products as for its Grade A clean area standard preparation production system.
In addition, Hempmon will push the following 4 aspects.work.
A. Hempmon will build a 9,000 square meters building on QC and R&D entrusted by department of science and technology of Yunnan province, which will be one of the domestic industrial hemp research bases and an authoritative third-party industrial hemp testing institution
B. Hempmon will conduct research on high value development and utilization of industrial hemp, and develop healthy & safe series of industrial hemp products in the field of food and health care products cooperating with partners.
C. Hempmon will explore CBD biosynthesis technology for future upgrading to cope with the possible shortage of raw materials and high production costs.
D. Hempmon will build the an industrial hemp museum and the industrial hemp plant factory workshop to popularize industrial hemp knowledge. That will demonstrate to the public display industrial hemp harvest their crop from the growth, maturity, and to the whole process of extraction, processing, and the application in the field of industrial hemp in biological medicine health value for all-round introduction and promotion.
Hansu CBD extract technology authorized Patent by the United States. The Patent is the international patent for medical extraction of cannabinoid in China (METHOD FOR EXTRACTION CANNABIDIOL FROM CANNABI).Hansu CBD application for drug master document has also been approved by FDA, becoming a Chinese manufacturer with DMF.
Hempmon expects to be completed and put into operation by the end of 2019, and the annual profit is in the hundreds of millions. Hempmon will supply a full complement of production capacity for the international market of non-toxic cannabinoids in short.